Retension Pharmaceuticals, Inc. (RTSN) Stock Price & Analysis
Retension Pharmaceuticals, Inc. (RTSN) closed at USD 12.21 on Thursday, October 15, 2026, up 4.90% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 11.64; the Oct 15, 2026 session ranged USD 11.56–12.86 on volume of 131,024 shares. Market capitalization is $101.73M, with a 52-week range of USD 9.66–12.86 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RTSN.md
Key facts (RTSN)
- Analysts: None.
- Total return with dividends: 1Y +15.9% vs S&P 500 +18.1%; 5Y +15.9% vs S&P 500 +85.1%.
Analysts (RTSN)
Consensus None.
Total return (dividends reinvested) (RTSN)
| 1Y (from 2026-10-09) | 5Y (from 2026-10-05) | |
|---|---|---|
| Total return | +15.9% | +15.9% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 48.3% | 75.5% |
| Max drawdown | +0.0% (→) | +0.0% (→) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 12.21 |
|---|---|
| Change | ▲ 4.90% (up) |
| Previous Close | USD 11.64 |
| Open | USD 11.56 |
| Day Range | USD 11.56 – 12.86 |
| 52-Week Range | USD 9.66 – 12.86 |
| Volume | 131,024 shares |
| Market Cap | $101.73M |
| Exchange | NCM |
Analyst Ratings (RTSN)
Wall Street analysts rate RTSN "None", per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | None |
|---|
Earnings (RTSN)
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (RTSN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 5.61 |
| Total Cash | $13.49M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (RTSN)
Nexqual rates Retension Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $13M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$12M (TTM) |
| Efficiency | Mixed — No data |
Ownership (RTSN)
| Insider Ownership | +18.27% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 8.33M |
| Float | 678,613 |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (RTSN)
Retension Pharmaceuticals, Inc. is led by Eric Keller (age 60), Co-founder, CEO & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| Co-founder, CEO & Director | Eric Keller (age 60) |
|---|---|
| Executive Chairman | Michael Joseph Berendt (age 76) |
| Chief Financial Officer | Alexander Duke Schwartz (age 39) |
| Executive Vice President of Clinical Development & Operations | LeAnne Bloedon M.S. |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt